Eneboparatide Normalized Serum Calcium and Achieved Independence From Active Vitamin D and Oral Calcium Supplements in 31.1% of Adults With Hypoparathyroidism at Week 24 in CALYPSO Phase III Trial
May 13, 2026
May 13, 2026
WILMINGTON, Delaware, May 13 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Eneboparatide normalized serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial
Urinary calcium excretion was normalized in 56.6% of patients who were hypercalciuric at baseline
Additional results through week 52 fur . . .
* * *
Eneboparatide normalized serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial
Urinary calcium excretion was normalized in 56.6% of patients who were hypercalciuric at baseline
Additional results through week 52 fur . . .